Minicircle

Founder backgrounds

• Follistatin Gene Therapy

  Minicircle's flagship therapy is a non-viral minicircle DNA plasmid encoding follistatin, a natural inhibitor of myostatin. It is administered as a subcutaneous injection at partner clinics and is intended to produce transient, non-heritable expression that the company associates with increased lean muscle mass, reduced body fat percentage and changes in epigenetic age markers in early participants. The product is investigational, has not been reviewed by the FDA, and is offered to consenting adults outside the United States.

• Klotho Gene Therapy

  A second minicircle DNA plasmid therapy, in development and slated for partner-clinic availability in 2026, encoding the longevity-associated protein klotho. Klotho expression has been linked in preclinical literature to kidney, cardiovascular and cognitive aging pathways. As with follistatin, the therapy is designed to be non-integrating and transient, delivered via subcutaneous injection and offered as an investigational product through international partner clinics rather than through the US regulatory pathway.

• Minicircle Plasmid Platform

  Underlying both therapies is a non-viral minicircle plasmid platform that uses small, circular DNA constructs stripped of bacterial backbone sequences to deliver target genes without viral vectors and without integrating into the host genome. The platform is designed for relatively low-cost manufacturing and rapid iteration on new gene targets across longevity, metabolic and performance indications, and underpins the company's ambition to offer a pipeline of patient-pays gene therapies through international clinic partners.